Company profile
CV Sciences, Inc.
OTC: CVSI · Healthcare · Drug Manufacturers - Specialty & Generic
#592 of 1,418 Healthcare companies by revenue31st-percentile growth
EA Score
56CFH 56DQ 60GM 51SS 50
v0.1 · 65/100 weight · provisional
↑ growth stability, disclosure history · ↓ revenue growth (YoY), Altman-Z
Methodology →Revenue TTM
$13.4M
Rev growth YoY (TTM)
-12.6%
Net income (FY)
-$958.0k
Employees
43
as of 2026-08-24
Market cap
$4.1M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.8M$13.8M2025
Net income-$958.0k-$958.0k2025
Operating income-$470.0k-$470.0k2025
Total assets$7.0M$7.0M2025
Liabilities$5.5M$5.5M2025
Equity$1.5M$1.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Shipping and Handling100%
By geography
Not disclosed.
The read
What is CV Sciences, Inc.’s revenue?
CV Sciences, Inc. booked $13.8M in FY2025 revenue, contracting 12% year over year — slower than 69% of Healthcare companies we track, at a -6.9% net margin.
Peers · Healthcare
Healthcare Triangle, Inc.40DPyxis Oncology, Inc.28DBiotricity, Inc.——Hyperfine, Inc.44DCapsoVision, Inc.37DMicrobix Biosystems Inc.60CNeighbors
San Diego →Key facts
CEOJoseph D. Dowling
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSan Diego, CA
ExchangeOTC: CVSI
Employees43
IPO date2013-02-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.